Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
77.40
-0.19 (-0.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
June 21, 2022
Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses
From
Moderna, Inc.
Via
AccessWire
Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
June 17, 2022
mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
June 08, 2022
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant
From
Moderna, Inc.
Via
AccessWire
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
June 07, 2022
mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trialmRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
June 02, 2022
CAMBRIDGE, MA / ACCESSWIRE / June 2, 2022 / Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the European...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna to Present at Upcoming Conferences in June 2022
June 01, 2022
CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the...
From
Moderna, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
May 31, 2022
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna to Present at the UBS 2022 Global Healthcare Conference
May 18, 2022
CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a...
From
Moderna, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
May 18, 2022
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
May 17, 2022
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery Moderna's 5th Annual Science and...
From
Moderna, Inc.
Via
AccessWire
Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer
May 11, 2022
CAMBRIDGE, MA / ACCESSWIRE / May 11, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that its recently appointed...
From
ModernaTX, Inc
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Moderna to Host Annual Science and Technology Day on May 17, 2022
May 09, 2022
CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its...
From
Moderna, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
May 04, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union
April 29, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada
April 29, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Moderna, Inc.
Via
AccessWire
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Arpa Garay Joins Moderna as Chief Commercial Officer
April 27, 2022
CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
April 19, 2022
Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
April 13, 2022
CAMBRIDGE, MA / ACCESSWIRE / April 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live...
From
Moderna, Inc.
Via
AccessWire
Jorge Gomez Joins Moderna as Chief Financial Officer
April 11, 2022
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
April 11, 2022
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle CAMBRIDGE, MA / ACCESSWIRE / April...
From
Moderna, Inc.
Via
AccessWire
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
April 07, 2022
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / April 7, 2022 /...
From
Moderna, Inc.
Via
AccessWire
Topics
Death
Exposures
COVID-19
Death
Moderna Launches New Charitable Foundation
April 04, 2022
Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19 CAMBRIDGE, MA / ACCESSWIRE / April 4, 2022 /...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Launches New Charitable Foundation
April 04, 2022
SOURCE: Moderna
Via
3BL Media
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
March 29, 2022
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age CAMBRIDGE, MA / ACCESSWIRE / March 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight...
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
March 24, 2022
- COVID-19 vaccine Phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint with robust neutralizing antibody titers similar to adults. Moderna is moving forward...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Moderna Finalizes Strategic Partnership with Australian Government
March 23, 2022
On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc....
From
Moderna, Inc.
Via
AccessWire
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
March 23, 2022
- Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.